Holen Sie sich die Stockscreener-App
3.00
1.01%
0.03
Handel nachbörslich:
3.02
0.02
+0.67%
Quantum Biopharma Ltd Aktie (QNTM) Neueste Nachrichten
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Executive Outlines Lucid-MS Development Strategy and Commerc - Benzinga
Quantum BioPharma Ltd (QNTM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Quantum BioPharma Ltd (QNTM) Institutional Confidence - TradingKey
5 Stocks To BUY HEAVY Before June 2026 Pentagone Ovnis (6uU0VmOjAy) - Mshale
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Revenue Breakdown – FWB:0K91 - TradingView
Quantum BioPharma Ltd (QNTM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Revenue Breakdown – SWB:0K91 - TradingView
QNTM|Quantum BioPharma Ltd|Price:3.010|Chg%:+0.020 - TradingKey
Quantum BioPharma Ltd (QNTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
QNTM|Quantum BioPharma Ltd|Price:2.935|Chg%:-0.055 - TradingKey
QNTM|Quantum BioPharma Ltd|Price:2.950|Chg%:-0.020 - TradingKey
QNTM|Quantum BioPharma Ltd|Price:3.035|Chg%:+0.065 - TradingKey
Quantum BioPharma Ltd (QNTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quantum Biopharma Ltd. (QNTM) Slides 2.1% as Support Levels Come into FocusSmall Cap Breakouts - dars.gov.et
Quantum BioPharma Ltd (QNTM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
QNTM: Quantum BioPharma Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Quantum BioPharma Ltd (QNTM) Fundamental & Financial Data - Stocktwits
Quantum BioPharma (QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions - TradingView
Quantum BioPharma Plans to Settle Debt - marketscreener.com
Press Release: Quantum BioPharma Announces Intention to Settle Debt - Moomoo
Quantum BioPharma Announces Intention to Settle Debt - Sahm
Quantum BioPharma Ltd. Announces CAD$123,487 Debt Settlement Through Share Issuance - Quiver Quantitative
Quantum Biopharma Ltd. (QNTM) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy - USA Today
Quantum BioPharma (QNTM) Expands Clinical Development of Neuroprotective Therapy - NewMediaWire
Quantum Biopharma (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development Of Neuroprotective Therapy - Menafn
Quantum BioPharma Advances Multiple Sclerosis Therapy LUCID-MS into Phase 2 Trials - citybuzz -
Why Quantum BioPharma (QNTM) Is 'One to Watch' - NewMediaWire
Why Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’ - Benzinga
Why Quantum Biopharma (NASDAQ: QNTM) (CSE: QNTM) Is 'One To Watch' - Menafn
Quantum BioPharma Advances Diversified Pipeline Targeting Neurodegenerative and Metabolic Disorders - citybuzz -
Quantum Biopharma Ltd. Q4 2025 Earnings: Widening Loss Amid Pre-Revenue Drug DevelopmentEarnings Volatility Report - DonanımHaber
Quantum Biopharma Ltd. (QNTM) Q4 2025 Earnings: Biotech Firm Reports Wider-Than-Expected Loss as Stock SlipsLow Estimate Range - dars.gov.et
AdvisorShares Trust holds 203,564 Class B shares in Quantum Biopharma (QNTM) - Stock Titan
Quantum BioPharma Provides Corporate Update - BNN Bloomberg
QNTM Should I Buy - Intellectia AI
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast - The Globe and Mail
Quantum BioPharma (QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast - Yahoo Finance
QNTM Q4 2025 Earnings: Biotech Reports Loss with No Revenue, Stock DeclinesEarnings Surprise Score - dars.gov.et
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study - The Globe and Mail
Quantum BioPharma (QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study - Yahoo Finance
Quantinuum (QNTM) Receives Strong Ratings, Shares Rise 5% in Pre-Market - GuruFocus
Quantum Biopharma Q4 2025 Earnings: Reports net loss of $0.71 per share as clinical‑stage biotech continues operationsFinancial Summary - dars.gov.et
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Actuals & Estimates (BOATS:QNTM) - TradingView
QNTM Forecast — Price Target — Prediction for 2027 - TradingView
Quantum BioPharma Reaches Midpoint in MS Imaging Study, Early Results Show Promise - citybuzz -
Quantum BioPharma's Lucid-MS Targets Underlying Cause of Multiple Sclerosis in Growing $38.6B Market - citybuzz -
NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis - The Manila Times
NetworkNewsAudio Announces Audio Press Release (APR) the - GlobeNewswire
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Actuals & Estimates (NASDAQ:QNTM) - TradingView
1.49%
2.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):